Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06604897 · ClinicalTrials.gov registry record
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
A clinical trial of Essential Hypertension, sponsored by Novartis.
- Active
- Registry status
- 1,405
- Enrollment target
- 1
- Study location
NCT06604897 is a study of Essential Hypertension that is active but no longer recruiting, run by Novartis. The registered enrollment target is 1,405 participants, above the 628-participant average among 8 other Essential Hypertension trials with a reported enrollment target (124% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06604897, a study of Essential Hypertension, is active but no longer recruiting, sponsored by Novartis.
- ACTIVE NOT RECRUITING
- Registry status
- 1,405 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study will be used as secondary use of collected patient information in the database (Japan Medical Data Survey \[JAMDAS\]) owned by M3 Inc. JAMDAS is a database that aggregates medical information and is constructed mainly from electronic medical record information of general practices, allowing real-time extraction of information entered in medical records, such as prescription status including drug switching and continuation, laboratory values, clinical evaluation scores, and comorbidities, etc.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,405 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2025-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06604897
The ClinicalTrials.gov registry entry for NCT06604897 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,405 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 628-participant average among 8 other Essential Hypertension trials with a reported enrollment target (124% higher). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT06604897 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06604897 about?
NCT06604897 is a clinical study titled "Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension". This study is a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study will be used as secondary use of collected patient information in the database (Japan Medical Data Survey \[JAMDAS\]) owned by M3 Inc. JAMDAS is a database that aggregat...
What is the current status of trial NCT06604897?
This trial is currently active not recruiting. The enrollment target is 1,405 participants. The study started on 2023-01-31. Estimated completion is 2025-03-31.
What conditions does trial NCT06604897 study?
This clinical trial studies the following conditions: Essential Hypertension.
Who is sponsoring clinical trial NCT06604897?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06604897 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Uric Acid in Essential Hypertension in Children
COMPLETED · Phase 2
-
Hypertension: Prediction of Biofeedback Success
COMPLETED · Phase 1
-
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
COMPLETED · NA
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.